Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07249775 · ClinicalTrials.gov registry record
A First-in-Human Study of FID-022 in Solid Tumor Patients
A clinical trial of Pancreatic Cancer and Cancer Cachexia, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT07249775 is a study of Pancreatic Cancer and Cancer Cachexia that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 120 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07249775, a study of Pancreatic Cancer and Cancer Cachexia, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This observational study aims to (1) validate a multimodal artificial intelligence (AI) model for early detection of cancer-associated cachexia in pancreatic cancer patients and (2) assess the feasibility and acceptability of diet and exercise interventions for cachexia management. The study will use retrospective data from the Florida Pancreas Collaborative and prospective data from newly diagnosed patients at Moffitt Cancer Center.
Conditions Studied
Interventions
- OTHER Baseline Lifestyle and Symptom Assessment
- OTHER Extended Lifestyle Monitoring
- OTHER Feasibility Survey
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-10-08 |
| Est. Completion | 2026-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07249775
The ClinicalTrials.gov registry entry for NCT07249775 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (69% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Baseline Lifestyle and Symptom Assessment is the first listed.
NCT07249775 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07249775 about?
NCT07249775 is a clinical study titled "A First-in-Human Study of FID-022 in Solid Tumor Patients". This observational study aims to (1) validate a multimodal artificial intelligence (AI) model for early detection of cancer-associated cachexia in pancreatic cancer patients and (2) assess the feasibility and acceptability of diet and exercise interventions for cachexia management. The study will us...
What is the current status of trial NCT07249775?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2025-10-08. Estimated completion is 2026-10.
What conditions does trial NCT07249775 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Cancer Cachexia.
What interventions are being tested in trial NCT07249775?
The interventions under investigation include: Baseline Lifestyle and Symptom Assessment (OTHER), Extended Lifestyle Monitoring (OTHER), Feasibility Survey (OTHER).
Who is sponsoring clinical trial NCT07249775?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07249775 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.